For most of the past decade, Amgen was a reliable but slow-moving machine: a biotech giant that grew revenues at roughly the pace of the broader economy, collected fat margins, and returned cash to shareholders while its older blockbusters aged. Then two things happened almost simultaneously. The company spent $28 billion to acquire Horizon Therapeutics in 2023, adding a clutch of rare-disease drugs and a new growth engine. And the weight-loss drug revolution, led by Novo Nordisk and Eli Lilly, turned every pharmaceutical company’s pipeline into a referendum on whether it had a GLP-1 answer. Amgen had one in development. The stock has not been the same since.
Today the shares sit near their all-time high, up more than half over the past twelve months. The filed numbers show a business that is genuinely growing faster than it used to. The question the math forces is whether the price already assumes that acceleration continues, or whether it assumes something more. That gap is the story.
First, the shape of it
The filed revenue record shows Amgen growing at roughly 10% a year in its most recent periods, after years of near-stagnation. The stock’s price-to-sales ratio, a measure of what investors pay for each dollar of revenue, sits at its highest point in our decade of data, at the 99th percentile of its own history. Those two readings pull in opposite directions: the business is accelerating, but the price already assumes that acceleration is both real and durable. The open question is what happens if the growth is real but merely good, rather than exceptional. At the 99th percentile of its own valuation history, “merely good” may not be enough.
What the filings actually show
The 10-K for fiscal year 2025 shows full-year revenue rising 10% in 2025, with a net margin of 21%. That margin recovery matters: in 2024, the Horizon integration costs pushed the margin down sharply, so 2025 represents a return to the company’s historical profitability range rather than a new peak. The 10-Q for Q2 2026 extends the trend: total revenues grew 10% from a year earlier, with free cash flow of $3.5 billion, nearly double the amount generated in Q2 2025. That cash generation is the kind of number that earns patience from investors.
The growth is real, and it is coming from specific places. Repatha, a cholesterol-lowering drug, grew more than a third year-over-year in Q2 2026. EVENITY, for osteoporosis, and TEZSPIRE, for severe asthma, each grew by similar magnitudes. These are not incremental improvements; they are drugs taking share in large markets. CEO Robert Bradway noted on the Q2 2026 earnings call that “our six key growth drivers grew 26% year over year, generating nearly 70% of second-quarter product sales.” That concentration is worth holding in mind: most of the growth story lives in a handful of products.
The other side of the ledger
While those six drivers sprint, older franchises are walking backward fast. Prolia, once a cornerstone of Amgen’s bone-health business, saw sales fall roughly a third year-over-year in Q2 2026 as biosimilar competitors arrived globally. XGEVA dropped by a similar magnitude over the same period. Enbrel, the rheumatoid arthritis drug that was Amgen’s biggest revenue source for years, fell again in Q2 2026, and the price it commands dropped sharply because the Inflation Reduction Act’s Medicare price-setting mechanism, which took effect at the start of 2026, now limits what Amgen can charge. As Insurance Business Magazine reported, biosimilars and the IRA are actively reshaping how drug spending flows through the system, and Amgen sits on both sides of that shift: it benefits as a biosimilar maker, and it bleeds as a branded-drug seller.
BMO Capital Markets, in a September 8 downgrade to Market Perform, put the concern plainly: commercial execution is largely priced in, and the company faces “significant loss-of-exclusivity headwinds across key franchises including Prolia/XGEVA, Enbrel, Otezla, and Kyprolis.” That is a list of drugs that collectively represent a large share of today’s revenue, and all of them face structural pressure that does not go away.
The weight of MariTide
The bull case for Amgen at this price rests heavily on MariTide, its obesity drug candidate. MariTide is a monthly injectable, designed to be dosed as few as four to six times a year, competing against weekly injections from Novo Nordisk and Eli Lilly. Phase 2 data presented in June 2026 showed up to 20% weight loss at 52 weeks, with no plateau, which is a meaningful clinical signal. Amgen has nine Phase 3 studies running and is spending roughly $2.6 billion in capital expenditures this year alone to build manufacturing capacity for weight-management products.
But MariTide has no approval date. Phase 3 readouts are expected in 2027 at the earliest. Oral GLP-1 pills from Novo Nordisk and Eli Lilly are already approved and on shelves. The regulatory timeline means that even a clean Phase 3 result leaves a multi-year gap before meaningful revenue. Amgen discontinued two earlier obesity candidates along the way, a reminder that the path from Phase 2 data to pharmacy shelf is long and uncertain.
On September 8, a Novartis cardiovascular trial failed, and because Amgen’s olpasiran targets a similar mechanism in heart disease, the stock fell sharply that day. The market’s reaction illustrated the fragility embedded in a price that leans on pipeline promises: one piece of adjacent bad news can erase months of gains in a session.
What the price assumes
Our data puts Amgen’s current price-to-earnings ratio meaningfully above its own decade median, and the price-to-sales ratio at the 99th percentile of its own history. To translate that into human terms: investors are paying more for each dollar of Amgen’s revenue today than they have in essentially any other moment over the past ten years. That premium, spread across the company’s full revenue base, amounts to roughly a year’s worth of sales sitting in the stock price purely as an expectation above historical norms.
The analyst consensus, per MarketBeat data from September 2026, implies earnings growth of about 6% between 2026 and 2027. Amgen’s own raised guidance, issued after Q2 2026, targets full-year 2026 revenue of $38.2 billion to $39.4 billion. If revenue lands at the midpoint of that range and the company sustains its current margin, the math at the decade-median multiple would put the stock well below today’s price. Reaching the current level on the math alone would require either margins expanding meaningfully beyond their recent recovery, or earnings growth accelerating well past what the consensus projects, or both. The mood, meaning what the market is currently paying, is running well ahead of what the filed trend alone would justify.
GuruFocus, using a discounted cash flow model as of September 8, put intrinsic value at roughly $296. Argus, maintaining a positive rating on August 21, lifted its target to $460. The range of informed opinion is wide, which is itself informative: the valuation depends almost entirely on assumptions about MariTide and the pipeline that the filings cannot yet confirm.
Reading the numbers
- Revenue growth, FY2025: 10%, to $36.8 billion. What it means: after years of near-flat growth, Amgen is expanding at a pace that justifies investor attention. The catch is that 2024’s 18.6% jump included the first full year of Horizon revenues, a one-time step-up. A household budget analogy: if a family’s income jumped 18% one year because a spouse returned to work, and 10% the next, the trend looks strong, but the 18% was partly a structural shift, not a repeatable acceleration.
- P/S ratio at 99th percentile: 6.4 against a decade median of 5.2. What it means: for every dollar of annual revenue Amgen generates, the market is paying $6.40. At the decade median, it would pay $5.20. The difference across $36.8 billion of revenue is roughly $44 billion of market value, about what Amgen earns in revenue over a full year, sitting in the price purely as a premium above historical norms.
- Free cash flow, Q2 2026: $3.5 billion in a single quarter, nearly double the year-earlier period. What it means: cash generation is strong and accelerating, which funds both the MariTide buildout and the dividend. A business generating this much cash has real options. The risk is that $2.6 billion of this year’s capital spending is going into manufacturing capacity for a drug that has not yet cleared Phase 3.
- Prolia sales, Q2 2026: down 32% year-over-year. What it means: biosimilar competition is not a future risk for this franchise; it is an active revenue drain right now. A product that generated roughly $1.1 billion in Q2 a year ago generated $759 million in Q2 2026. That gap, annualized, is larger than the entire quarterly revenue of many mid-sized biotechs.
- Consensus EPS growth, 2026 to 2027: roughly 6%, per MarketBeat analyst estimates. What it means: the analysts who follow this company most closely expect earnings to grow at about the pace of a mature, stable business, not a high-growth one. A P/E of 30.7 is typically the price tag on a company growing earnings at 15% or more. Paying that multiple for 6% growth is a bet that something changes the trajectory, and right now that something has a name: MariTide.
Sources
- Amgen 10-Q, quarter ended June 30, 2026 (SEC EDGAR)
- Amgen 10-K, fiscal year ended December 31, 2025 (SEC EDGAR)
- Amgen Q2 2026 earnings call transcript (Motley Fool, August 11, 2026)
- Amgen Q4 2025 earnings call transcript (Motley Fool, February 3, 2026)
- Biosimilars and IRA pricing reshaping drug spend (Insurance Business Magazine)
- Cantor Fitzgerald neutral rating; BMO downgrade (MarketBeat, September 8, 2026)
- Analyst EPS estimates for FY2027 (MarketBeat, September 1, 2026)
- GuruFocus DCF valuation, September 8, 2026
- MariTide Phase 3 switch study and Phase 2 data (TIKR)
- MariTide regulatory status (FormBlends)
